Biochemical pathogenesis of aspirin exacerbated respiratory disease (AERD)

Clinical Biochemistry

Volumn 46, Issue 7-8, 2013, Pages 566-578

  Narayanankutty, Arun ^a,b   Reséndiz Hernández, Juan Manuel ^a   Falfán Valencia, Ramcés ^a   Teran, Luis M ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

AERD; Arachidonic acid metabolism; Aspirin; Asthma; Cyclooxygenase; Cysteinyl leukotrienes; Eicosanoid; Lipoxygenase; PGE2

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYTOCHROME P450; HYDROLASE; ICOSANOID; LEUKOTRIENE; LIPOXIN; LIPOXYGENASE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE;

ARACHIDONIC ACID METABOLISM; ASPIRIN EXACERBATED RESPIRATORY DISEASE; BIOCHEMISTRY; BIOSYNTHESIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; ICOSANOID METABOLISM; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; METABOLISM; PATHOPHYSIOLOGY;

ARACHIDONIC ACID; ASTHMA, ASPIRIN-INDUCED; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; HUMANS; LIPOXINS; LIPOXYGENASES;

EID: 84884747518     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.12.005     Document Type: Review

References (151)

1. Widal M.F., Abrami P., Lermeyez J. Anaphylaxie et idiosyncrasie. Presse Med 1922, 30:189-192.
2. Samter M., Beers R.F. Concerning the nature of intolerance to aspirin. J Allergy 1967, 40:281-293.
3. Samter M., Beers R.F. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968, 68:975-983.
4. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232-235.
5. Szczeklik A., Gryglewski R.J., Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975, 1:67-69.
6. Varga E.M., Jacobson M.R., Masuyama K., Rak S., Till S.J., Darby Y., et al. Inflammatory cell populations and cytokine mRNA expression in the nasal mucosa in aspirin-sensitive rhinitis. Eur Respir J 1999, 14:610-615.
7. Mascia K., Haselkorn T., Deniz Y.M., Miller D.P., Bleecker E.R., Borish L., et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005, 116:970-975.
8. Jankowski R., Bouchoua F., Coffinet L., Vignaud J.M. Clinical factors influencing the eosinophil infiltration of nasal polyps. Rhinology 2002, 40:173-178.
9. Mita H., Endoh S., Kudoh M., Kawagishi Y., Kobayashi M., Taniguchi M., et al. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy 2001, 56:1061-1067.
10. Palikhe N.S., Kim S.H., Cho B.Y., Ye Y.M., Hur G.Y., Park H.S. Association of three sets of high-affinity IgE receptor (FcepsilonR1) polymorphisms with aspirin-intolerant asthma. Respir Med 2008, 102:1132-1139.
11. Kim S.H., Bae J.S., Holloway J.W., Lee J.T., Suh C.H., Nahm D.H., et al. A polymorphism of MS4A2 (-109T>C) encoding the beta-chain of the high-affinity immunoglobulin E receptor (FcepsilonR1beta) is associated with a susceptibility to aspirin-intolerant asthma. Clin Exp Allergy 2006, 36:877-883.
12. Lee J.Y., Kim H.M., Ye Y.M., Bahn J.W., Suh C.H., Nahm D., et al. Role of staphylococcal superantigen-specific IgE antibodies in aspirin-intolerant asthma. Allergy Asthma Proc 2006, 27:341-346.
13. Togo K., Suzuki Y., Yoshimaru T., Inoue T., Terui T., Ochiai T., et al. Aspirin and salicylates modulate IgE-mediated leukotriene secretion in mast cells through a dihydropyridine receptor-mediated Ca(2+) influx. Clin Immunol 2009, 131:145-156.
14. Alcorn J.F., Crowe C.R., Kolls J.K. TH17 cells in asthma and COPD. Annu Rev Physiol 2010, 72:495-516.
15. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 2009, 5:625-630.
16. Sousa A.R., Lams B.E., Pfister R., Christie P.E., Schmitz M., Lee T.H. Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways. Am J Respir Crit Care Med 1997, 156:1384-1389.
17. Carpagnano G.E., Resta O., Gelardi M., Spanevello A., Di Gioia G., Giliberti T., et al. Exhaled inflammatory markers in aspirin-induced asthma syndrome. Am J Rhinol 2007, 21:542-547.
18. Kupczyk M., Kurmanowska Z., Kupryś-Lipińska I., Bocheńska-Marciniak M., Kuna P. Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge. Respir Med 2010, 104:1404-1409.
19. Kowalski M.L., Lewandowska-Polak A., Woźniak J., Ptasińska A., Jankowski A., Wagrowska-Danilewicz M., et al. Association of stem cell factor expression in nasal polyp epithelial cells with aspirin sensitivity and asthma. Allergy 2005, 60:631-637.
20. Shome G.P., Tarbox J., Shearer M., Kennedy R. Cytokine expression in peripheral blood lymphocytes before and after aspirin desensitization in aspirin-exacerbated respiratory disease. Allergy Asthma Proc 2007, 28:706-710.
21. Steinke J.W., Payne S.C., Borish L. Interleukin-4 in the generation of the AERD phenotype: implications for molecular mechanisms driving therapeutic benefit of aspirin desensitization. J Allergy (Cairo) 2012 2012, 182090.
22. Kim S.H., Ye Y.M., Lee S.K., Choi J.H., Holloway J.W., Park C.S., et al. Association of TNF-alpha genetic polymorphism with HLA DPB1*0301. Clin Exp Allergy 2006, 36:1247-1253.
23. Falfán-Valencia R., Pavón-Romero G.F., Camarena A., García Mde L., Galicia-Negrete G., Negrete-García M.C., et al. The IL1B-511 polymorphism (rs16944 AA genotype) is increased in aspirin-exacerbated respiratory disease in Mexican population. J Allergy (Cairo) 2012 2012, 741313.
24. Kim B.S., Park S.M., Uhm T.G., Kang J.H., Park J.S., Jang A.S., et al. Effect of single nucleotide polymorphisms within the interleukin-4 promoter on aspirin intolerance in asthmatics and interleukin-4 promoter activity. Pharmacogenet Genomics 2010, 20:748-758.
25. Kohyama K., Abe S., Kodaira K., Yukawa T., Hozawa S., Sagara H., et al. IL-13 and IL-17A gene polymorphisms in Japanese patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2011, 107:510-516.
26. Kim S.H., Park H.S., Holloway J.W., Shin H.D., Park C.S. Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients. Respir Med 2007, 101:490-495.
27. Chilton F.H., Rudel L.L., Parks J.S., Arm J.P., Seeds M.C. Mechanisms by which botanical lipids affect inflammatory disorders. Am J Clin Nutr 2008, 87:498S-503S.
28. Ghosh M., Tucker D.E., Burchett S.A., Leslie C.C. Properties of the Group IV phospholipase A2 family. Prog Lipid Res 2006, 45:487-510.
29. Lambeau G., Gelb M.H. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 2008, 77:495-520.
30. Leslie C.C. Properties and regulation of cytosolic phospholipase A2. J Biol Chem 1997, 272:16709-16712.
31. Folco G., Murphy R.C. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 2006, 58:375-388.
32. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182.
33. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases(cyclooxygenases)-1 and -2. J Biol Chem 1996, 271:33157-33160.
34. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci 2002, 99:13926-13931.
35. Simmons D.L., Botting R.M., Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004, 56:387-437.
36. Mastalerz L., Sanak M., Gawlewicz-Mroczka A., Gielicz A., Cmiel A., Szczeklik A. Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax 2008, 63:27-34.
37. Ferreri N.R., Howland W.C., Stevenson D.D., Spiegelberg H.L. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988, 137:847-854.
38. Picado C., Fernandez-Morata J.C., Juan M., Roca-Ferrer J., Fuentes M., Xaubet A., et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1999, 160:291-296.
39. Adamusiak A.M., Stasikowska-Kanicka O., Lewandowska-Polak A., Danilewicz M., Wagrowska-Danilewicz M., Jankowski A., et al. Expression of arachidonate metabolism enzymes and receptors in nasal polyps of aspirin-hypersensitive asthmatics. Int Arch Allergy Immunol 2012, 157:354-362.
40. Pierzchalska M., Soja J., Woś M., Szabó Z., Nizankowska-Mogielnicka E., Sanak M., et al. Deficiency of cyclooxygenases transcripts in cultured primary bronchial epithelial cells of aspirin-sensitive asthmatics. J Physiol Pharmacol 2007, 58:207-218.
41. Shi J., Misso N.L., Duffy D.L., Bradley B., Beard R., Thompson P.J., et al. Cyclooxygenase-1 gene polymorphisms in patients with different asthma phenotypes and atopy. Eur Respir J 2005, 26:249-256.
42. Morgan T., Bajrovic N., Silar M., Kosnik M., Korosec P. Aspirin-induced COX-2 overexpression in monocytes of aspirin-intolerant patients. Int Arch Allergy Immunol 2009, 149:378-384.
43. Roca-Ferrer J., Garcia-Garcia F.J., Pereda J., Perez-Gonzalez M., Pujols L., Alobid I., et al. Reduced expression of COXs and production of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma. J Allergy Clin Immunol 2011, 128:66-72.
44. Gyllfors P., Bochenek G., Overholt J., Drupka D., Kumlin M., Sheller J., et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003, 111:1116-1121.
45. Umemoto J., Tsurikisawa N., Nogi S., Iwata K., Oshikata C., Tatsuno S., et al. Selective cyclooxygenase-2 inhibitor cross-reactivity in aspirin-exacerbated respiratory disease. Allergy Asthma Proc 2011, 32:259-261.
46. Vancheri C., Mastruzzo C., Sortino M.A., Crimi N. The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol 2004, 25:40-46.
47. Bauman K.A., Wettlaufer S.H., Okunishi K., Vannella K.M., Stoolman J.S., Huang S.K., et al. The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest 2010, 120:1950-1960.
48. Coward W.R., Watts K., Feghali-Bostwick C.A., Knox A., Pang L. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol 2009, 29:4325-4339.
49. Park J.Y., Pillinger M.H., Abramson S.B. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 2006, 119:229-240.
50. Murakami M., Nakatani Y., Tanioka T., Kudo I. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat 2002, 68-69:383-399.
51. Woodward D.F., Jones R.L., Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15years of progress. Pharmacol Rev 2011, 63:471-538.
52. http://www.iuphar-db.org/DATABASE/FamilyMenuForward?familyId=58.
53. Wasserman M.A. Pharmacologic and therapeutic implications of prostaglandins on airway smooth muscle. Bull Eur Physiopathol Respir 1981, 17:675-686.
54. Szczeklik A., Mastalerz L., Nizankowska E., Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med 1996, 153:567-571.
55. Sestini P., Armetti L., Gambaro G., Pieroni M.G., Refini R.M., Sala A., et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996, 153:572-575.
56. Celik G., Bavbek S., Misirligil Z., Melli M. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E(2) on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients. Clin Exp Allergy 2001, 31:1615-1622.
57. Rådmark O., Samuelsson B. 5-Lipoxygenase: mechanisms of regulation. J Lipid Res 2009, 50(Suppl.):S40-S45.
58. Long J.A., Fogel-Petrovic M., Knight D.A., Thompson P.J., Upham J.W. Higher prostaglandin e2 production by dendritic cells from subjects with asthma compared with normal subjects. Am J Respir Crit Care Med 2004, 170:485-491.
59. Sladek K., Dworski R., Soja J., Sheller J.R., Nizankowska E., Oates J.A., et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994, 149:940-946.
60. Aggarwal S., Moodley Y.P., Thompson P.J., Misso N.L. Prostaglandin E2 and cysteinyl leukotriene concentrations in sputum: association with asthma severity and eosinophilic inflammation. Clin Exp Allergy 2010, 40:85-93.
61. Trudeau J., Hu H., Chibana K., Chu H.W., Westcott J.Y., Wenzel S.E. Selective downregulation of prostaglandin E2-related pathways by the Th2 cytokine IL-13. J Allergy Clin Immunol 2006, 117:1446-1454.
62. Ying S., Meng Q., Scadding G., Parikh A., Corrigan C.J., Lee T.H. Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. J Allergy Clin Immunol 2006, 117:312-318.
63. Jinnai N., Sakagami T., Sekigawa T., Kakihara M., Nakajima T., Yoshida K., et al. Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum Mol Genet 2004, 13:3203-3217.
64. Kim S.H., Kim Y.K., Park H.W., Jee Y.K., Kim S.H., Bahn J.W., et al. Association between polymorphisms in prostanoid receptor genes and aspirin-intolerant asthma. Pharmacogenet Genomics 2007, 17:295-304.
65. Urade Y., Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 2000, 1482:259-271.
66. Kanaoka Y., Urade Y. Hematopoietic prostaglandin D synthase. Prostaglandins Leukot Essent Fatty Acids 2003, 69:163-167.
67. Oguma T., Asano K., Ishizaka A. Role of prostaglandin D(2) and its receptors in the pathophysiology of asthma. Allergol Int 2008, 57:307-312.
68. Suzuki-Yamamoto T., Nishizawa M., Fukui M., Okuda-Ashitaka E., Nakajima T., Ito S., et al. cDNA cloning, expression and characterization of human prostaglandin F synthase. FEBS Lett 1999, 462:335-340.
69. Komoto J., Yamada T., Watanabe K., Takusagawa F. Crystal structure of human prostaglandin F synthase (AKR1C3). Biochemistry 2004, 43:2188-2198.
70. Schieber A., Frank R.W., Ghisla S. Purification and properties of prostaglandin 9-ketoreductase from pig and human kidney. Identity with human carbonyl reductase. Eur J Biochem 1992, 206:491-502.
71. Basu S. Novel cyclooxygenase-catalyzed bioactive prostaglandin F2alpha from physiology to new principles in inflammation. Med Res Rev 2007, 27:435-468.
72. Chiang C.W., Yeh H.C., Wang L.H., Chan N.L. Crystal structure of the human prostacyclin synthase. J Mol Biol 2006, 364:266-274.
73. Hecker M., Ullrich V. On the mechanism of prostacyclin and thromboxane A2 biosynthesis. J Biol Chem 1989, 264:141-150.
74. Oh S.H., Kim Y.H., Park S.M., Cho S.H., Park J.S., Park C.S., et al. Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients. Pharmacogenomics 2011, 12:351-363.
75. Kim S.H., Choi J.H., Park H.S., Holloway J.W., Lee S.K., Park C.S., et al. Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma. Clin Exp Allergy 2005, 35:585-590.
76. Kohyama K., Hashimoto M., Abe S., Kodaira K., Yukawa T., Hozawa S., et al. Thromboxane A2 receptor +795T>C and chemoattractant receptor-homologous molecule expressed on Th2 cells -466T>C gene polymorphisms in patients with aspirin-exacerbated respiratory disease. Mol Med Report 2012, 5:477-482.
77. Higashi N., Taniguchi M., Mita H., Osame M., Akiyama K. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Clin Exp Allergy 2002, 32:1484-1490.
78. Bochenek G., Nagraba K., Nizankowska E., Szczeklik A. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003, 111:743-749.
79. Higashi N., Mita H., Ono E., Fukutomi Y., Yamaguchi H., Kajiwara K., et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol 2010, 125:1084-1091.
80. Song W.L., Wang M., Ricciotti E., Fries S., Yu Y., Grosser T., et al. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J Biol Chem 2008, 283:1179-1188.
81. Higashi N., Mita H., Yamaguchi H., Fukutomi Y., Akiyama K., Taniguchi M. Urinary tetranor-PGDM concentrations in aspirin-intolerant asthma and anaphylaxis. J Allergy Clin Immunol 2012, 129:557-559.
82. Palikhe N.S., Kim S.H., Cho B.Y., Ye Y.M., Choi G.S., Park H.S. Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease. Allergy 2010, 65:338-346.
83. Palikhe N.S., Kim S.H., Ye Y.M., Hur G.Y., Cho B.Y., Park H.S. Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria. Pharmacogenomics 2009, 10:375-383.
84. Murphy R.C., Gijón M.A. Biosynthesis and metabolism of leukotrienes. Biochem J 2007, 405:379-395.
85. Cowburn A.S., Sladek K., Soja J., Adamek L., Nizankowska E., Szczeklik A., et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998, 101:834-846.
86. Adamjee J., Suh Y.J., Park H.S., Choi J.H., Penrose J.F., Lam B.K., et al. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J Pathol 2006, 209:392-399.
87. Choi J.H., Park H.S., Oh H.B., Lee J.H., Suh Y.J., Park C.S., et al. Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase. Hum Genet 2004, 114:337-344.
88. Kim S.H., Bae J.S., Suh C.H., Nahm D.H., Holloway J.W., Park H.S. Polymorphism of tandem repeat in promoter of 5-lipoxygenase in ASA-intolerant asthma: a positive association with airway hyperresponsiveness. Allergy 2005, 60:760-765.
89. Brash A.R., Boeglin W.E., Chang M.S. Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci 1997, 94:6148-6152.
90. Funk C.D., Furci L., FitzGerald G.A. Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. Proc Natl Acad Sci 1990, 87:5638-5642.
91. Brinckmann R., Schnurr K., Heydeck D., Rosenbach T., Kolde G., Kühn H. Membrane translocation of 15-lipoxygenase in hematopoietic cells is calcium-dependent and activates the oxygenase activity of the enzyme. Blood 1998, 91:64-74.
92. Hagmann W., Gao X., Zacharek A., Wojciechowski L.A., Honn K.V. 12-Lipoxygenase in Lewis lung carcinoma cells: molecular identity, intracellular distribution of activity and protein, and Ca(2+)-dependent translocation from cytosol to membranes. Prostaglandins 1995, 49:49-62.
93. Song Y.S., Yang E.M., Kim S.H., Jin H.J., Park H.S. Effect of genetic polymorphism of ALOX15 on aspirin-exacerbated respiratory disease. Int Arch Allergy Immunol 2012, 159:157-161.
94. Peters-Golden M., Henderson W.R. Leukotrienes. N Engl J Med 2007, 357:1841-1854.
95. Lam B.K., Penrose J.F., Xu K., Baldasaro M.H., Austen K.F. Site-directed mutagenesis of human leukotriene C4 synthase. J Biol Chem 1997, 272:13923-13928.
96. Bäck M., Dahlén S.E., Drazen J.M., Evans J.F., Serhan C.N., Shimizu T., et al. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev 2011, 63:539-584.
97. http://www.iuphar-db.org/DATABASE/FamilyMenuForward?familyId=35.
98. Antczak A., Montuschi P., Kharitonov S., Gorski P., Barnes P.J. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002, 166:301-306.
99. Gaber F., Daham K., Higashi A., Higashi N., Gülich A., Delin I., et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 2008, 63:1076-1082.
100. Mortaz E., Redegeld F.A., Nijkamp F.P., Engels F. Aspirin induces the production of the inflammatory mediator 8-epi-PGF in mast cells. Eur J Pharmacol 2006, 543(1-3):190-193.
101. Arm J.P., O'Hickey S.P., Spur B.W., Lee T.H. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Respir Dis 1989, 140:148-153.
102. Higashi N., Taniguchi M., Mita H., Kawagishi Y., Ishii T., Higashi A., et al. Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 2004, 113:277-283.
103. Christie P.E., Tagari P., Ford-Hutchinson A.W., Charlesson S., Chee P., Arm J.P., et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991, 143:1025-1029.
104. Knapp H.R., Sladek K., Fitzgerald G.A. Increased excretion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Med 1992, 119:48-51.
105. Micheletto C., Visconti M., Tognella S., Facchini F.M. Dal Negro RW. Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls. Eur Ann Allergy Clin Immunol 2006, 38:20-23.
106. Cai Y., Bjermer L., Halstensen T.S. Bronchial mast cells are the dominating LTC4S-expressing cells in aspirin-tolerant asthma. Am J Respir Cell Mol Biol 2003, 29:683-693.
107. Steinke J.W., Bradley D., Arango P., Crouse C.D., Frierson H., Kountakis S.E., et al. Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J Allergy Clin Immunol 2003, 111:342-349.
108. Torres-Galván M.J., Ortega N., Sánchez-García F., Blanco C., Carrillo T., Quiralte J. LTC4-synthase A-444C polymorphism: lack of association with NSAID-induced isolated periorbital angioedema in a Spanish population. Ann Allergy Asthma Immunol 2001, 87:506-510.
109. Sanak M., Simon H.U., Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997, 350:1599-1600.
110. Kawagishi Y., Mita H., Taniguchi M., Maruyama M., Oosaki R., Higashi N., et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002, 109:936-942.
111. Van Sambeek R., Stevenson D.D., Baldasaro M., Lam B.K., Zhao J., Yoshida S., et al. 5' flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol 2000, 106:72-76.
112. Kedda M.A., Shi J., Duffy D., Phelps S., Yang I., O'Hara K., et al. Characterization of two polymorphisms in the leukotriene C4 synthase gene in an Australian population of subjects with mild, moderate, and severe asthma. J Allergy Clin Immunol 2004, 113:889-895.
113. Tornhamre S., Ehnhage A., Kölbeck K.G., Edenius C., Lindgren J.A. Uncoupled regulation of leukotriene C4 synthase in platelets from aspirin-intolerant asthmatics and healthy volunteers after aspirin treatment. Clin Exp Allergy 2002, 32:1566-1573.
114. Hirata H., Arima M., Fukushima Y., Honda K., Sugiyama K., Tokuhisa T., et al. Over-expression of the LTC4 synthase gene in mice reproduces human aspirin-induced asthma. Clin Exp Allergy 2011, 41:1133-1142.
115. Sousa A.R., Parikh A., Scadding G., Corrigan C.J., Lee T.H. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002, 347:1493-1499.
116. Ozen Z., Mumbuc S., Sari I., Baglam T., Karatas E., Kanlikama M. Cysteinyl leukotriene receptor expression in aspirin-sensitive nasal polyposis patients. ORL J Otorhinolaryngol Relat Spec 2007, 69:176-180.
117. Kim S.H., Oh J.M., Kim Y.S., Palmer L.J., Suh C.H., Nahm D.H., et al. Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin Exp Allergy 2006, 36:433-439.
118. Park J.S., Chang H.S., Park C.S., Lee J.H., Lee Y.M., Choi J.H., et al. Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet Genomics 2005, 15:483-492.
119. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008, 8:349-361.
120. Romano M., Recchia I., Recchiuti A. Lipoxin receptors. ScientificWorldJournal 2007, 7:1393-1412.
121. Hashimoto A., Hayashi I., Murakami Y., Sato Y., Kitasato H., Matsushita R., et al. Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis. J Rheumatol 2007, 34:2144-2153.
122. Levy B.D. Lipoxins and lipoxin analogs in asthma. Prostaglandins Leukot Essent Fatty Acids 2005, 73:231-237.
123. Karp C.L., Flick L.M., Park K.W., Softic S., Greer T.M., Keledjian R., et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004, 5:388-392.
124. Kupczyk M., Antczak A., Kuprys-Lipinska I., Kuna P. Lipoxin A4 generation is decreased in aspirin-sensitive patients in lysine-aspirin nasal challenge in vivo model. Allergy 2009, 64:1746-1752.
125. Celik G.E., Erkekol F.O., Misirligil Z., Melli M. Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity. Clin Exp Allergy 2007, 37:1494-1501.
126. Yamaguchi H., Higashi N., Mita H., Ono E., Komase Y., Nakagawa T., et al. Urinary concentrations of 15-epimer of lipoxin A(4) are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma. Clin Exp Allergy 2011, 41:1711-1718.
127. Sanak M., Levy B.D., Clish C.B., Chiang N., Gronert K., Mastalerz L., et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000, 16:44-49.
128. Kim H.J., Cho S.H., Park J.S., Lee T.H., Lee E.J., Kim Y.H., et al. Association analysis of formyl peptide receptor 2 (FPR2) polymorphisms and aspirin exacerbated respiratory diseases. J Hum Genet 2012, 57:247-253.
129. Feltenmark S., Gautam N., Brunnström A., Griffiths W., Backman L., Edenius C., et al. Eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. Proc Natl Acad Sci 2008, 105:680-685.
130. Claesson H.E. On the biosynthesis and biological role of eoxins and 15-lipoxygenase-1 in airway inflammation and Hodgkin lymphoma. Prostaglandins Other Lipid Mediat 2009, 89:120-125.
131. Ono E., Mita H., Taniguchi M., Higashi N., Hasegawa M., Miyazaki E., et al. Concentration of 14,15-leukotriene C4 (eoxin C4) in bronchoalveolar lavage fluid. Clin Exp Allergy 2009, 39:1348-1352.
132. Sachs-Olsen C., Sanak M., Lang A.M., Gielicz A., Mowinckel P., Szczeklik A., et al. Eoxins: a new inflammatory pathway in childhood asthma. J Allergy Clin Immunol 2010, 126:859-867.
133. Pace-Asciak C.R. The hepoxilins and some analogues: a review of their biology. Br J Pharmacol 2009, 158:972-981.
134. Nigam S., Zafiriou M.P., Deva R., Ciccoli R. Roux-Van der Merwe R. Structure, biochemistry and biology of hepoxilins: an update. FEBS J 2007, 274:3503-3512.
135. Mrsny R.J., Gewirtz A.T., Siccardi D., Savidge T., Hurley B.P., Madara J.L., et al. Identification of hepoxilin A3 in inflammatory events: a required role in neutrophil migration across intestinal epithelia. Proc Natl Acad Sci 2004, 101:7421-7426.
136. Jacobs E.R., Zeldin D.C. The lung HETEs (and EETs) up. Am J Physiol Heart Circ Physiol 2001, 280:H1-H10.
137. Spector A.A. Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res 2009, 50(Suppl.):S52-S56.
138. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285:1276-1279.
139. Polonikov A.V., Ivanov V.P., Solodilova M.A., Khoroshaya I.V., Kozhuhov M.A., Panfilov V.I. Promoter polymorphism G-50T of a human CYP2J2 epoxygenase gene is associated with common susceptibility to asthma. Chest 2007, 132:120-126.
140. Bednar M.M., Gross C.E., Russell S.R., Fuller S.P., Ahern T.P., Howard D.B., et al. 16(R)-hydroxyeicosatetraenoic acid, a novel cytochrome P450 product of arachidonic acid, suppresses activation of human polymorphonuclear leukocyte and reduces intracranial pressure in a rabbit model of thromboembolic stroke. Neurosurgery 2000, 47:1410-1418.
141. Yildirim Yaroǧlu H., Calikoǧlu M., Tamer Gümüş L. CYP2C19 gene polymorphism may be a risk factor for bronchial asthma. Med Princ Pract 2011, 20:39-42.
142. Kohyama K., Abe S., Kodaira K., Yukawa T., Hozawa S., Morioka J., et al. Polymorphisms of the CYP2C19 gene in Japanese patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2011, 128:1117-1120.
143. Milne G.L., Yin H., Morrow J.D. Human biochemistry of the isoprostane pathway. J Biol Chem 2008, 283:15533-15537.
144. Janssen L.J. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am J Physiol Lung Cell Mol Physiol 2001, 280:L1067-L1082.
145. Kunapuli P., Lawson J.A., Rokach J., FitzGerald G.A. Functional characterization of the ocular prostaglandin f2alpha (PGF2alpha) receptor. Activation by the isoprostane, 12-iso-PGF2alpha. J Biol Chem 1997, 272:27147-27154.
146. Takahashi K., Nammour T.M., Fukunaga M., Ebert J., Morrow J.D., Roberts L.J., et al. Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors. J Clin Invest 1992, 90:136-141.
147. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal 2008, 10:1405-1434.
148. Voynow J.A., Kummarapurugu A. Isoprostanes and asthma. Biochim Biophys Acta 2011, 1810:1091-1095.
149. Janssen L.J., Premji M., Netherton S., Coruzzi J., Lu-Chao H., Cox P.G. Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles. Br J Pharmacol 2001, 132:127-134.
150. Zahler S., Becker B.F. Indirect enhancement of neutrophil activity and adhesion to cultured human umbilical vein endothelial cells by isoprostanes (iPF2alpha-III and iPE2-III). Prostaglandins Other Lipid Mediat 1999, 57:319-331.
151. Schäfer D., Maune S. Pathogenic mechanisms and in vitro diagnosis of AERD. J Allergy (Cairo) 2012, 2012:789232.